What are prophylactic antibiotics in bronchiectasis?

Prophylactic antibiotics in bronchiectasis are antibiotics taken over a prolonged period to reduce flare-ups, also called exacerbations. They are different from a short rescue course prescribed when symptoms suddenly worsen.

During an exacerbation, you may become more breathless, produce more sputum, notice a change in sputum colour, cough more, or feel generally unwell with a chest infection. A rescue antibiotic course is intended to treat that acute deterioration. Prophylactic treatment is intended to reduce how often these episodes occur.

In bronchiectasis, the airways become abnormally widened and more prone to mucus build-up. Mucus can trap bacteria, leading to repeated infection, inflammation, coughing and further airway irritation. This is sometimes described as the vicious cycle of bronchiectasis.

Long-term antibiotics aim to interrupt this cycle. In selected patients, they may reduce the number of chest infections, increase the time between flare-ups, reduce bacterial load in sputum and improve day-to-day symptoms.

Key principle

Antibiotics do not cure bronchiectasis and do not replace airway clearance, exercise, vaccination or treatment of the underlying causes and associated conditions.

UK guidance traditionally advises considering long-term antibiotics in people who have three or more exacerbations per year. More recent European guidance supports considering treatment in patients at higher risk of future flare-ups, which may include two or more exacerbations per year, one exacerbation with severe daily symptoms, or a severe exacerbation requiring hospital care.

Why might my specialist suggest long-term antibiotics?

Your respiratory team may suggest prophylactic antibiotics when infections continue to return despite good basic bronchiectasis care.

Before recommending long-term treatment, your team will usually review airway clearance, sputum results, vaccination, inhaler technique where relevant, reflux management and treatment of associated conditions such as asthma, COPD, immune deficiency or allergic bronchopulmonary aspergillosis.

Long-term antibiotics may be considered if you:

Have three or more flare-ups each year
Need repeated rescue antibiotic courses
Repeatedly grow the same bacteria in sputum
Have chronic Pseudomonas aeruginosa infection
Remain unwell between infections
Take a long time to recover after flare-ups
Have required hospital treatment
Have a higher risk of severe infection

The treatment threshold may be lower for people who remain highly symptomatic between infections or who are at increased risk of a severe exacerbation.

Oral versus nebulised antibiotics: what is the difference?

Oral antibiotics

Oral antibiotics are taken as tablets or capsules. They work throughout the body, are straightforward to take and suit many patients.

Nebulised antibiotics

Nebulised antibiotics are inhaled through a nebuliser. They deliver a high antibiotic concentration directly into the airways with less exposure to the rest of the body.

Nebulised treatment can be particularly useful when bacteria remain persistently in the lungs, especially Pseudomonas aeruginosa.

The choice depends on sputum results, infection pattern, allergies, kidney function, hearing or balance problems, heart rhythm risk, other medicines and your ability to use and maintain a nebuliser.

Neither option is better for everyone

The most appropriate treatment is the option that targets the bacteria most likely to be causing problems, reduces exacerbations, remains safe and fits realistically into daily life.

Guideline recommendations in simple terms

When Pseudomonas aeruginosa is present

For people with chronic Pseudomonas aeruginosa infection, UK guidance recommends inhaled colistin as a first option and inhaled gentamicin as a second-line alternative.

Azithromycin or erythromycin may be considered when inhaled antibiotics are unsuitable or not tolerated. A macrolide may sometimes be added when exacerbations remain frequent despite inhaled treatment.

When chronic Pseudomonas is not present

For people without chronic Pseudomonas infection, UK guidance recommends azithromycin or erythromycin as the usual first long-term options.

Inhaled gentamicin may be considered as an alternative. Doxycycline may be used when macrolides are not tolerated or have not been effective.

European guidance also supports long-term macrolides for many patients at high risk of exacerbations and inhaled antibiotics for chronic Pseudomonas infection.

Azithromycin in bronchiectasis

Azithromycin is one of the most frequently used oral prophylactic antibiotics in bronchiectasis. It belongs to a group of antibiotics called macrolides.

It may help in two ways. It acts against some bacteria and also has anti-inflammatory effects within the airways. This may partly explain why it can reduce exacerbations even when it does not directly eradicate every organism identified in sputum.

Common dosing patterns

Common specialist regimens include azithromycin 250 mg three times each week, 500 mg three times each week, or 250 mg daily. A lower intermittent dose may be used initially to reduce side effects, with adjustment according to response and tolerance.

Why NTM testing matters

Before starting azithromycin, your team will usually request sputum testing for non-tuberculous mycobacteria, commonly shortened to NTM.

Macrolides are important components of treatment for several NTM infections. Using a macrolide alone when active NTM infection is present can encourage resistance and make the infection more difficult to treat later.

Your team may also arrange an ECG to assess heart rhythm, liver blood tests and a review of any previous hearing or balance problems.

Possible side effects include nausea, loose stools, abdominal discomfort, altered taste, hearing or balance symptoms, liver test changes, heart rhythm effects in susceptible patients and antibiotic resistance. Many patients tolerate azithromycin well, especially when treatment begins with a lower intermittent dose.

Doxycycline, co-trimoxazole and other oral options

Doxycycline

Doxycycline is not usually the first-choice long-term antibiotic for bronchiectasis, but it may help selected patients. UK guidance lists it as an alternative when macrolides are not tolerated or have not worked in non-Pseudomonas bronchiectasis.

Possible side effects include indigestion, sensitivity to sunlight and irritation of the oesophagus. Taking it with plenty of water and remaining upright afterwards can reduce oesophageal irritation. Doxycycline is generally avoided during pregnancy.

Co-trimoxazole

Co-trimoxazole may be used in selected cases when sputum cultures identify susceptible bacteria and other options are unsuitable. It is not usually the main guideline choice for routine long-term bronchiectasis prevention.

It can interact with other medicines and may require blood tests to monitor kidney function, potassium levels and blood cell counts.

Other oral antibiotics may occasionally be selected according to sputum culture results, previous response, allergies, tolerance and local antimicrobial guidance.

Long-term strategy

Specialists usually continue the same effective long-term oral antibiotic rather than rotating antibiotics every month. If it stops working, treatment can be changed according to sputum sensitivity results and clinical response.

Nebulised colomycin, colistin, tobramycin and gentamicin

Nebulised colomycin is a brand name for colistimethate sodium, commonly called colistin. It is frequently used for chronic Pseudomonas aeruginosa infection in bronchiectasis.

Nebulised antibiotics may suit people who repeatedly grow Pseudomonas in sputum and continue to experience frequent infections. Delivering the antibiotic directly to the airways can reduce bacterial load and may reduce exacerbations.

What does the evidence show?

A large systematic review of inhaled antibiotics found that they reduced the proportion of patients experiencing exacerbations, modestly reduced exacerbation frequency, probably reduced severe exacerbations and produced small improvements in symptoms and quality of life.

The review also found an increase in antibiotic-resistant organisms, which is one reason regular specialist review remains important.

Airway side effects and challenge testing

Nebulised colistin can cause cough, wheeze, chest tightness or throat irritation. Many clinics therefore perform a supervised test dose or challenge test while the patient is stable before regular treatment begins.

Tobramycin and gentamicin are aminoglycoside antibiotics. They may be given by nebuliser in selected patients depending on local practice and sputum results.

Aminoglycosides require caution in people with kidney impairment, hearing loss, tinnitus, balance disorders or those using other medicines that may affect the kidneys or hearing. Long-term inhaled aminoglycosides are generally avoided when kidney function is severely reduced.

Advantages of prophylactic antibiotics

The main potential benefit is fewer bronchiectasis exacerbations. This may mean fewer rescue antibiotic courses, fewer days confined to bed, fewer urgent medical appointments and fewer hospital admissions.

Some patients also notice less sputum, fewer changes in sputum colour, reduced cough and improved energy. The extent of benefit varies between individuals.

Set a measurable treatment goal

Long-term treatment should have a clear purpose. Examples include reducing exacerbations from five per year to two, avoiding hospital admission, reducing daily sputum burden or improving recovery time.

A clear goal makes it easier for you and your specialist to judge whether the treatment is worthwhile.

Disadvantages and risks

The main long-term concern is antibiotic resistance. This occurs when bacteria become less sensitive to an antibiotic over time. Resistance does not always mean treatment has failed, but it may reduce future treatment options.

Oral treatment risks

Stomach upset, diarrhoea, thrush, skin rashes, liver test changes, medicine interactions, heart rhythm effects and hearing or balance symptoms.

Nebulised treatment risks

Cough, wheeze, chest tightness, throat irritation and the practical burden of preparing, using and cleaning nebuliser equipment.

Clinics reduce these risks through careful patient selection, sputum testing, ECGs, blood tests, supervised nebuliser trials, dose adjustment and regular review.

What monitoring should patients expect?

Before treatment begins, your respiratory team may request several baseline checks.

Recent bacterial sputum cultures
NTM sputum testing before macrolides
ECG before azithromycin
Liver function blood tests
Kidney function blood tests
Review of hearing, tinnitus and balance
Medication interaction review
Supervised inhaled antibiotic challenge

After starting treatment, monitoring may follow a sequence such as:

Review early side effects and confirm that the treatment is being taken correctly.
Repeat liver blood tests approximately one month after starting a macrolide.
Repeat an ECG after approximately one month where appropriate to look for new QT prolongation.
Review sputum cultures, exacerbation frequency, symptoms and treatment adherence.
Perform a formal benefit and safety review at approximately six and 12 months.

Treatment should be stopped or changed if it does not produce a meaningful benefit or if side effects outweigh the advantages.

Some specialists may consider a planned treatment break during a lower-risk period, such as summer, when this can be done without increasing exacerbation risk. Long-term antibiotics should not be stopped or restarted without medical advice.

What can you do alongside antibiotics?

Prophylactic antibiotics work best as part of a complete bronchiectasis treatment plan advised by your respiratory team.

Continue airway clearance

Airway clearance remains central to treatment. A respiratory physiotherapist can teach techniques suited to your symptoms, sputum volume, lung function and daily routine.

Remain physically active where possible.
Keep recommended vaccinations up to date.
Send sputum samples when symptoms change.
Drink adequate fluid unless you have been advised to restrict fluids.
Avoid smoking and seek cessation support where needed.
Use inhalers, nebulisers and airway-clearance devices as instructed.

Keep an exacerbation diary

Record the dates of flare-ups, changes in symptoms, sputum colour, antibiotics used, side effects and recovery time. This provides useful evidence when assessing whether prophylactic treatment is working.

Conclusion

Prophylactic antibiotics can make a meaningful difference for the right person with bronchiectasis. They are usually considered when exacerbations remain frequent or severe, particularly when sputum cultures identify persistent bacteria such as Pseudomonas aeruginosa.

Oral options such as azithromycin are convenient and have strong evidence for reducing exacerbations. Doxycycline, co-trimoxazole and other oral antibiotics may help selected patients when guided by sputum results and tolerance.

Nebulised options such as colistin, tobramycin and gentamicin can target bacteria directly within the lungs, especially in chronic Pseudomonas infection.

Treatment should be tailored to sputum results, exacerbation pattern, side-effect risk, other medical conditions and patient preferences. The goal is fewer infections and better disease control with proportionate, sensible monitoring.

Frequently asked questions

Who needs prophylactic antibiotics in bronchiectasis?

A specialist may consider prophylactic antibiotics if you continue to have frequent flare-ups, often three or more per year, despite good airway clearance and standard care. The threshold may be lower when infections are severe, require hospital treatment or are followed by poor recovery.

Is azithromycin safe to take long term?

Azithromycin can be safe and effective for many patients, but appropriate checks are needed. These may include sputum testing for NTM, an ECG, liver blood tests, medication review and follow-up monitoring.

Why should macrolides be avoided if NTM is present?

Macrolides are important drugs for treating several NTM infections. Taking a macrolide alone when active NTM is present can encourage resistance and make future treatment more difficult.

Are nebulised antibiotics stronger than tablets?

They are not simply stronger. They work differently. Nebulised antibiotics deliver high concentrations directly into the lungs and may be particularly useful for chronic airway infection, especially Pseudomonas. Oral antibiotics may be more suitable for other infection patterns.

Will I need prophylactic antibiotics forever?

Not necessarily. Your specialist should review whether the treatment reduces flare-ups, improves symptoms and remains safe. Treatment may be changed, paused or stopped if it is not helping or if side effects outweigh the benefits.

Prophylactic Antibiotics in Bronchiectasis: Why, How, and What You Should Know